Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which manages over USD 4 billion in assets and investment in over 280 companies.

Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN) and U-Systems (acquired by GE Healthcare).

Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, CanSino Biotechnology, New Horizon Bio and Berry Oncology among others.  Her other investments include Acea Biosciences, Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics and Jacobio.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently a visiting lecturer at Harvard Law School and council member of HKUST Business School. She also serves on the Board of Trustees of the Hotchkiss School and board member of the Hong Kong Palace Museum.